F
Fabien Zoulim
Researcher at French Institute of Health and Medical Research
Publications - 716
Citations - 40988
Fabien Zoulim is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Hepatitis B virus & Hepatitis B. The author has an hindex of 96, co-authored 641 publications receiving 35807 citations. Previous affiliations of Fabien Zoulim include Hotel Dieu Hospital & University of Orléans.
Papers
More filters
Journal ArticleDOI
Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma.
Alexander L. Gerbes,Fabien Zoulim,Herbert Tilg,Jean-François Dufour,Jordi Bruix,Valérie Paradis,Riad Salem,Markus Peck-Radosavljevic,Peter R. Galle,Tim F. Greten,Jean-Charles Nault,Matías A. Avila +11 more
TL;DR: Therapeutic topics highlighted are locoregional techniques, combination therapies and the potential of immunotherapy, and a critical evaluation of novel targets and strategies for personalized treatment of HCC.
Journal ArticleDOI
How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach
TL;DR: New technologies that may allow more informed decision-making for response guided therapy in the battle against HBV are discussed, including next-generation sequencing to assess drug-resistant or immune escape variants and quasi-species heterogeneity in patients.
Journal ArticleDOI
Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development.
Leen Delang,Jan Paeshuyse,Inge Vliegen,Pieter Leyssen,Susan Obeid,I. David Durantel,Fabien Zoulim,Anne Op De Beeck,Johan Neyts +8 more
TL;DR: A combination of specific HCV inhibitors with statins may result in a more profound antiviral effect and may delay or prevent the development of resistance to such inhibitors.
Journal ArticleDOI
Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: An international multicenter cohort study
Jörg Petersen,Vlad Ratziu,Maria Buti,Harry L.A. Janssen,Ashley Brown,Pietro Lampertico,Jan Schollmeyer,Fabien Zoulim,Heiner Wedemeyer,Martina Sterneck,Thomas Berg,Christoph Sarrazin,Marc Lütgehetmann,Peter Buggisch +13 more
TL;DR: Rescue therapy with entecavir and tenofovir in CHB patients harboring viral resistance patterns or showing only partial antiviral responses to preceding therapies was efficient, safe, and well tolerated in patients with and without advanced liver disease.
Journal ArticleDOI
Mutations affecting the replication capacity of the hepatitis B virus
TL;DR: The genetic variability of the hepatitis B virus (HBV) encounters two compounding forces: a high viral copy number produced during active replication and the lack of proofreading activity in the HBV polymerase, resulting in a high mutational rate.